Difference between revisions of "Toremifene (Fareston)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA") |
Warner-admin (talk | contribs) m (Text replacement - "Category:Endocrine therapy" to "Category:Endocrine therapeutic") |
||
| Line 26: | Line 26: | ||
[[Category:Protein expression-specific medications]] | [[Category:Protein expression-specific medications]] | ||
| − | [[Category:Endocrine | + | [[Category:Endocrine therapeutic]] |
[[Category:Selective estrogen receptor modulators]] | [[Category:Selective estrogen receptor modulators]] | ||
Revision as of 17:30, 3 February 2019
General information
Class/mechanism: SERM (selective estrogen receptor modulator), with estrogen agonist/antagonist properties depending on tissue type.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Toremifene (Fareston) patient drug information (Chemocare)[4]
- Toremifene (Fareston) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 5/29/1997: Initial FDA approval
Also known as
- Brand names: Acapodene, Fareston